Literature DB >> 20372846

Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma.

Hiroshi Akahoshi1, Naota Taura, Tatsuki Ichikawa, Hisamitsu Miyaaki, Motohisa Akiyama, Satoshi Miuma, Eisuke Ozawa, Shigeyuki Takeshita, Toru Muraoka, Toshihisa Matsuzaki, Masashi Ohtani, Hajime Isomoto, Takehiro Matsumoto, Fuminao Takeshima, Kazuhiko Nakao.   

Abstract

The number and ratio of both HBsAg- and HCV Ab-negative hepatocellular carcinoma (HCC-nonBC) cases have been steadily increasing in Japan. The aim of this study was to examine the frequency of detection of HCC-nonBC by screening methods and to elucidate the clinical characteristics of HCC-nonBC compared with those of hepatitis C and/or B virus-associated HCC (HCC-virus). We recruited 624 patients with HCC who were diagnosed between 1982 and 2007 at the Department of Gastroenterology and Hepatology, Nagasaki University Hospital. They were categorized into 2 groups as follows: i) 550 were included in the HCC-virus group: positive for HBsAg and/or positive for HCV Ab, and ii) 74 were included in the HCC-nonBC group: negative for both HBsAg and HCV Ab. The follow-up patterns until the initial detection of HCC and the survival rates were analyzed and compared between the 2 groups. Multivariate analysis identified follow-up, alcohol consumption, albumin level, total bilirubin level, alpha-fetoprotein (AFP) level, and tumor-node-metastasis (TNM) stage as independent and significant risk factors for prognosis. Among the 397 patients with HCC in TNM stage I or II, multivariate analysis identified the cause of liver disease, gender, Child-Pugh score, serum albumin level and TNM stage as independent and significant risk factors for prognosis. We reported that the poor prognoses of patients with HCC-nonBC were attributable to its late detection in an advanced condition due to the absence of a surveillance system for the early detection of HCC. However, in early-stage patients, patients with HCC-nonBC showed significantly better prognosis than those in the HCC-virus group.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372846     DOI: 10.3892/or_00000766

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Authors:  Hiromi Kan; Sho-ichi Yamagishi; Ayako Ojima; Kei Fukami; Seiji Ueda; Masayoshi Takeuchi; Hideyuki Hyogo; Hiroshi Aikata; Kazuaki Chayama
Journal:  J Clin Lab Anal       Date:  2014-09-23       Impact factor: 2.352

Review 2.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

3.  Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival.

Authors:  Ryan T Groeschl; Johnny C Hong; Kathleen K Christians; Kiran K Turaga; Susan Tsai; Charles H C Pilgrim; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2013-06-19       Impact factor: 3.647

4.  Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma.

Authors:  Naota Taura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Eisuke Ozawa; Takuya Tsutsumi; Shotaro Tsuruta; Yuji Kato; Takashi Goto; Noboru Kinoshita; Masanori Fukushima; Hiroyuki Kato; Kazuyuki Ohata; Kazuo Ohba; Junichi Masuda; Keisuke Hamasaki; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Med Sci Monit       Date:  2013-09-06

Review 5.  Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Yanming Zhou; Xiaoying Si; Lupeng Wu; Xu Su; Bin Li; Zhiming Zhang
Journal:  World J Surg Oncol       Date:  2011-09-21       Impact factor: 2.754

6.  Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Akira Arimoto; Tomoko Wakasa; Ryuichi Kita; Toru Kimura; Yukio Osaki
Journal:  J Cancer       Date:  2013-07-18       Impact factor: 4.207

7.  Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma.

Authors:  Eyas Alkhalili; Alissa Greenbaum; Li Luo; Rodrigo Rodriguez; Katharine Caldwell; Oscar Munoz Estrada; Jacqueline O'Neill; Itzhak Nir; Katherine T Morris
Journal:  Ann Gastroenterol       Date:  2016-10-20

8.  Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma.

Authors:  Waled Mohsen; Marcia Rodov; Emilia Prakoso; Barbara Charlton; David G Bowen; David J Koorey; Nicholas A Shackel; Geoffrey W McCaughan; Simone I Strasser
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

9.  Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma.

Authors:  Amna Subhan Butt; Saeed Hamid; Ashfaq Ahmad Wadalawala; Mariam Ghufran; Ammar Asrar Javed; Omer Farooq; Bilal Ahmed; Tanveer Ul Haq; Wasim Jafri
Journal:  BMC Res Notes       Date:  2013-04-08

10.  Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus.

Authors:  Yoshihiro Okuda; Shugo Mizuno; Taizou Shiraishi; Yasuhiro Murata; Akihiro Tanemura; Yoshinori Azumi; Naohisa Kuriyama; Masashi Kishiwada; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Tomomi Yamada; Shuji Isaji
Journal:  Biomed Res Int       Date:  2014-03-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.